We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Biogen's (BIIB) MS Drug, Vumerity, Gets Positive CHMP Opinion
Read MoreHide Full Article
Biogen Inc. (BIIB - Free Report) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (“CHMP”) has rendered a positive opinion on, and has recommended marketing authorization to Vumerity (diroximel fumarate) for the treatment of adults with relapsing-remitting multiple sclerosis (“RRMS”). The opinion will now be reviewed by the European Commission.
The positive CHMP opinion was based on data from pharmacokinetic bridging studies that compared Vumerity to Biogen’s another multiple sclerosis (“MS”) drug, Tecfidera.
The CHMP assessed data from the multi-center, double-blind phase III EVOLVE-MS-2 study, which evaluated the gastrointestinal (“GI”) tolerability profile of Vumerity versus Tecfidera in patients with RRMS. Data from the same showed that the rate of overall treatment discontinuation was lower in patients who were treated with Vumerity compared with those who received Tecfidera. The treatment discontinuation rate due to GI tolerability was 0.8% in the Vumerity arm compared to 4.8% in the Tecfidera arm.
Vumerity, an oral fumarate, was approved in the United States for the treatment of relapsing forms of MS in adults in 2019. In the first six months of 2021, Vumerity recorded sales worth $164.6 million.
In late 2017, Biogen in-licensed worldwide commercialization rights to Vumerity from Alkermes (ALKS - Free Report) .
Shares of Biogen have rallied 22.6% so far this year compared with the industry’s growth of 0.9%.
Image Source: Zacks Investment Research
Biogen holds a strong position in the MS market, with a wide range of products, including Avonex, Tysabri, Tecfidera and Plegridy. However, multiple generic versions of Tecfidera have been launched, which are significantly eroding the drug’s sales.
The market remains challenging for Biogen’s MS products with newer, competitive entrants. The launch of Ocrevus, a new MS drug by Roche (RHHBY - Free Report) , is adversely impacting sales of Biogen’s MS franchise. However, Biogen receives royalties on U.S. sales of Ocrevus.
Biogen is working on consolidating its position in the MS market by bringing in new treatments.
Regeneron’s earnings estimates have been revised 17.8% upward for 2021 and 13.8% upward for 2022 over the past 60 days. The stock has surged 35% year to date.
See More Zacks Research for These Tickers
Pick one free report - opportunity may be withdrawn at any time
Image: Shutterstock
Biogen's (BIIB) MS Drug, Vumerity, Gets Positive CHMP Opinion
Biogen Inc. (BIIB - Free Report) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (“CHMP”) has rendered a positive opinion on, and has recommended marketing authorization to Vumerity (diroximel fumarate) for the treatment of adults with relapsing-remitting multiple sclerosis (“RRMS”). The opinion will now be reviewed by the European Commission.
The positive CHMP opinion was based on data from pharmacokinetic bridging studies that compared Vumerity to Biogen’s another multiple sclerosis (“MS”) drug, Tecfidera.
The CHMP assessed data from the multi-center, double-blind phase III EVOLVE-MS-2 study, which evaluated the gastrointestinal (“GI”) tolerability profile of Vumerity versus Tecfidera in patients with RRMS. Data from the same showed that the rate of overall treatment discontinuation was lower in patients who were treated with Vumerity compared with those who received Tecfidera. The treatment discontinuation rate due to GI tolerability was 0.8% in the Vumerity arm compared to 4.8% in the Tecfidera arm.
Vumerity, an oral fumarate, was approved in the United States for the treatment of relapsing forms of MS in adults in 2019. In the first six months of 2021, Vumerity recorded sales worth $164.6 million.
In late 2017, Biogen in-licensed worldwide commercialization rights to Vumerity from Alkermes (ALKS - Free Report) .
Shares of Biogen have rallied 22.6% so far this year compared with the industry’s growth of 0.9%.
Image Source: Zacks Investment Research
Biogen holds a strong position in the MS market, with a wide range of products, including Avonex, Tysabri, Tecfidera and Plegridy. However, multiple generic versions of Tecfidera have been launched, which are significantly eroding the drug’s sales.
The market remains challenging for Biogen’s MS products with newer, competitive entrants. The launch of Ocrevus, a new MS drug by Roche (RHHBY - Free Report) , is adversely impacting sales of Biogen’s MS franchise. However, Biogen receives royalties on U.S. sales of Ocrevus.
Biogen is working on consolidating its position in the MS market by bringing in new treatments.
Zacks Rank & Key Pick
Biogen currently carries a Zacks Rank #3 (Hold). A top-ranked stock in the biotech sector is Regeneron Pharmaceuticals, Inc. (REGN - Free Report) , which has a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Regeneron’s earnings estimates have been revised 17.8% upward for 2021 and 13.8% upward for 2022 over the past 60 days. The stock has surged 35% year to date.